<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088670</url>
  </required_header>
  <id_info>
    <org_study_id>SRX-1374-02</org_study_id>
    <nct_id>NCT03088670</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.</brief_title>
  <official_title>Evaluate Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SatRx LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SatRx LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that efficacy of Gosogliptin as Monotherapy and in Combination with Metformin
      is non-inferior to efficacy of Vildagliptin as Monotherapy and in combination with Metformin
      in the effects on glycosilated hemoglobin (HbA1c) at Week 12 and Week 36 compared to baseline
      (Week 0).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Screening of patients at Week -2

        -  Training for all complying patients in Diabetes Program School at Week -1 with
           glucometer and patient diary distribution for SMBG

        -  Randomization in one of two groups in the ratio 1:1.

        -  The 1st stage includes 12 weeks of monotherapy with Gosogliptin or Vildagliptin.

        -  The 2nd stage includes 24 weeks of combination therapy with Gosogliptin and Metformin or
           Vildagliptin and Metformin.

        -  Follow-up period of 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2013</start_date>
  <completion_date type="Actual">October 3, 2014</completion_date>
  <primary_completion_date type="Actual">March 30, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of HbA1c</measure>
    <time_frame>at Weeks 12 and 36 from baseline</time_frame>
    <description>Gosogliptin treatment group vs. Vildagliptin treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c level of ≤7%</measure>
    <time_frame>at Weeks 12 and 36 from baseline</time_frame>
    <description>Percent of patients who reach the target HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic episodes</measure>
    <time_frame>up to 36 week</time_frame>
    <description>Incidence of hypoglycemic episodes during the monotherapy and in combination with Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>at Weeks 12 and 36</time_frame>
    <description>Change of fasting plasma glucose from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Body Mass</measure>
    <time_frame>at Weeks 12 and 36</time_frame>
    <description>Change of Body Mass from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>up to 40 week</time_frame>
    <description>AE rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">299</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Gosogliptin treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of monotherapy and 24 weeks of combination with Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vildagliptin treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 weeks of monotherapy and 24 weeks of combination with Metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gosogliptin</intervention_name>
    <description>20 mg per day, dose titration to 30 mg per day at Week 4 as required Administration: orally</description>
    <arm_group_label>Gosogliptin treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>50 mg per day, dose titration to 100 mg per day at Week 4 as required (50 mg twice a day) Administration: orally</description>
    <arm_group_label>Vildagliptin treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1000 mg per day starting Week 12 (500 mg twice a day), dose titration to 2000 mg per day at Week 16 as required (1000 mg twice a day).
Administration: orally</description>
    <arm_group_label>Gosogliptin treatment group</arm_group_label>
    <arm_group_label>Vildagliptin treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women from 18 through 78 years

          2. Confirmed clinical diagnosis of type 2 diabetes mellitus

          3. Drug-naive patients or patients without hypoglycemic drug treatment at least till 12
             weeks before screening

          4. Patient's agreed to use adequate methods of contraception during the study

          5. Body mass index 22-40 kg/m2

          6. HbA1c 7.5 - 11.0%

          7. FPG &lt; 15 mmol/L

          8. Signed informed consent

          9. Patient's ability to follow all protocol requirements

        Exclusion Criteria:

          1. Pregnancy and lactation, women who plan to become pregnant during the clinical study,
             women of child-bearing potential (i.e. non-stylized surgically and in period of post
             menopause less than 2 years) without adequate methods of contraception.

          2. History of type 1 diabetes mellitus and other forms

          3. Severe metabolic complications of diabetes as ketoacidosis, hyperosmolar coma during 6
             weeks before screening

          4. Severe complication of diabetes, for instance proliferative retinopathy in active
             stage, autonomic neuropathy or gastroparesis

          5. A known allergy, hypersensitivity or contraindications to Gosogliptin, Vildagliptin,
             Metformin or their components

          6. Convulsive disorder; system autoimmune diseases or vascular collagenosis demanding the
             previous or current treatment by systemic corticosteroids, cytostatics; malignancy
             within the last 5 years (except for a basal-cell carcinoma);

          7. Significant cardiovascular diseases within 12 months of screening including: chronic
             heart failure of a class III or IV (NYHA), severe arrhythmia demanding treatment with
             antiarrhythmics, unstable angina, myocardial infarction, heart and coronary vessels
             surgery, heart valves diseases, transitory ischaemic attack or stroke, uncontrolled
             arterial hypertension with systolic Blood Pressure &gt; 180 mm Hg and diastolic Blood
             Pressure &gt; 110 mm Hg, pulmonary embolism or deep venous thrombosis

          8. A nephrotic syndrome, a chronic renal failure, serum creatinine &gt; 1.5 mg/dL (132
             µmol/L) in men and &gt; 1.4 mg/dL (123 µmol/L) in women or GFR &lt;60 ml/min/1.73m2

          9. HBV, HCV or a liver cirrhosis; AST or ALT &gt; 3 ULN; total bilirubin &gt; 2 ULN

         10. HIV; severe infection that can affect glycemia within 30 days of screening

         11. Anemia (Hb ≤10.5 g/dL in women or ≤11.5 g/dL in men); loss of &gt; 1 unit of blood ( 500
             mL) or blood transfusion within 12 weeks of screening

         12. Drugs or alcohol abuse

         13. Administration of any study drug within 30 days of screening

         14. Inability to read or write; unwillingness to understand and follow the protocol
             procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Non-state healthcare Organization &quot;Road Clinical Hospital at the station Chelyabinsk Open Joint Stock Company&quot; Russian Railways</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Healthcare Institution of Moscow &quot;Endocrinology Dispensary&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>119034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SEI HPE &quot;First Moscow State Medical University n.a. I.M. Sechenov of Ministry of Health and Social Development of the Russian Federation&quot;, Chair of faculty therapy #2 based at SHI of Moscow &quot;City clinical hospital #61&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>119048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Educational Institution higher professional education &quot;1st Moscow State Medical University n.a. I.M. Sechenov of the Ministry of Healthcare of Russian Federation&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;Clinical Hospital № 1&quot; of the Office of the President of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>121352</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Healthcare Institution of Moscow city &quot;City Clinical Hospital # 71 by the Department of Healthcare in Moscow&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>121374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Educational Institution of higher professional education &quot;1st Moscow State Medical University n.a. I.M. Sechenov of the Ministry of Healthcare of Russian Federation&quot; based on Endocrinology department of Hospital № 67 n.a L A Vorohobova</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SEI APE &quot;Russian Medical Academy of Postgraduate Education of Roszdrav&quot;, Chair of endocrinology and diabetology with course of endocrine surgery based at FSI &quot;Central Clinical hospital of civil aviation&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State budgetary institution &quot;Nizhny Novgorod Regional Clinical Hospital n.a Semashko</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Health Care Institution &quot;Perm Regional Hospital for War Veterans&quot;</name>
      <address>
        <city>Perm</city>
        <zip>614097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Perm State Medical Academy n.a. academician EA Wagner's &quot;Ministry of Health of the Russian Federation on the basis of Department of Endocrinology Regional Clinical Hospital</name>
      <address>
        <city>Perm</city>
        <zip>614990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI &quot;Republic Hospital n.a. V.A. Baranov&quot;</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State budgetary institution of Ryazan region &quot;City Clinical Hospital № 11&quot;</name>
      <address>
        <city>Ryazan</city>
        <zip>390037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State healthcare institution &quot;City Outpatient Clinic #37&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191119</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSHI &quot;Clinical Hospital #122 n.a. L.G. Sokolov of FMBA of Russia&quot;, Internal medicine department</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Health Care Institution Leningrad Regional Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Autonomous Noncommercial Organization &quot;Medical Centre &quot;XXI сentury&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State healthcare institution &quot;City Hospital of Saint Martyr Elizaveta&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSMEI HPE &quot;Military Medical Academy n.a. S.M. Kirov&quot; of the Ministry of Defence of the Russian Federation, 1st Internal medicine Chair of advanced training</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Diabetes Center &quot;LLC</name>
      <address>
        <city>Samara</city>
        <zip>443041</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Educational Institution higher professional education &quot;Saratov State Medical University n.a. V.I. Razumovsky&quot; of the Ministry of Healthcare of Russian Federation based on Clinical Hospital n.a S.R. Mirotvortsev</name>
      <address>
        <city>Saratov</city>
        <zip>, 410054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal health care institution &quot;City polyclinic №20</name>
      <address>
        <city>Saratov</city>
        <zip>410018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE &quot;Smolensk State Medical Academy&quot; of the Ministry of Health and Social Development of the Russian Federation, Center of clinical research of diagnostic and medicinal products, Chair of clinical pharmacology</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State budget educational institution of higher education &quot;Smolensk State Medical Academy,&quot; of Ministry of Health and Social Development of the Russian Federation on the basis of sanatorium SSMA</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State autonomous healthcare institution of Yaroslavl Region &quot;Сlinical hospital for emergency medical care n. a. N.V. Solovyov&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal clinical health institution Health Service Novo-Yaroslavl Oil Refinery</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI of Yaroslavl region &quot;Regional Clinical Hospital&quot;, Endocrinology department</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2017</study_first_submitted>
  <study_first_submitted_qc>March 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>March 18, 2017</last_update_submitted>
  <last_update_submitted_qc>March 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

